News Industry News Geisinger and Boehringer Ingelheim collaborate to create a predictive model to help improve health outcomes for people with type 2 diabetes at greatest risk of serious long-term complications, including cardiovascular death October 02, 2017
News Industry News Intarcia Announces Successful Cardiovascular Safety Results in Phase 3 FREEDOM-CVO Trial for ITCA 650, an Investigational Therapy for Type 2 Diabetes May 06, 2016
News Industry News Renova Therapeutics expands robust gene therapy intellectual property portfolio for cardiovascular and metabolic disease treatments January 03, 2016
News Industry News First CVD Outcome Trial of a GLP-1 Agonist Finds No Cardiac Risk or Benefit June 09, 2015